Estrace and Infusion site extravasation - a phase IV clinical study of FDA data

Summary:

Infusion site extravasation is reported as a side effect among people who take Estrace (estradiol), especially for people who are female, 60+ old, also take Epinephrine, and have Immunodeficiency common variable.

The phase IV clinical study analyzes which people have Infusion site extravasation when taking Estrace. It is created by eHealthMe based on reports of 16,282 people who have side effects when taking Estrace from the FDA, and is updated regularly.

What is Estrace?

Estrace has active ingredients of estradiol. It is often used in hormone replacement therapy. eHealthMe is studying from 16,703 Estrace users. Check the latest studies of Estrace.

What is Infusion site extravasation?

Infusion site extravasation (flow of (blood or lymph) from infusion site) is found to be associated with 649 drugs and 588 conditions by eHealthMe. Check the latest studies of Infusion site extravasation.

On Jul, 04, 2026

16,282 people reported to have side effects when taking Estrace.
Among them, 21 people (0.13%) have Infusion site extravasation.

Could Estrace cause Infusion site extravasation?

Among these 21 people:

What is the gender of people who have Infusion site extravasation when taking Estrace? *

female: 100 %
male: 0.0 %

What is the age of people who have Infusion site extravasation when taking Estrace? *

What are other drugs people take besides Estrace? *

Acetaminophen: 12 people, 57.14%
Epinephrine: 12 people, 57.14%
Vitamin D3: 10 people, 47.62%
Lidocaine: 9 people, 42.86%
Sodium Chloride: 9 people, 42.86%
Synthroid: 9 people, 42.86%
Proair Hfa: 9 people, 42.86%
Plaquenil: 6 people, 28.57%
Lasix: 6 people, 28.57%
Flonase Allergy Relief: 6 people, 28.57%

What are other side effects people have besides Infusion site extravasation? *

Urinary Tract Infection: 12 people, 57.14%
Weight Decreased: 9 people, 42.86%
Sinusitis (inflammation of sinus): 8 people, 38.10%
Infection: 7 people, 33.33%
Infusion Site Swelling: 6 people, 28.57%
Injection Site Pain: 6 people, 28.57%
Upper Respiratory Tract Infection: 6 people, 28.57%
Infusion Site Bruising: 5 people, 23.81%
Otitis (ear infection): 5 people, 23.81%
Infusion Site Warmth: 5 people, 23.81%

What are the existing conditions these people have? *

Immunodeficiency Common Variable: 18 people, 85.71%
Primary Immunodeficiency Syndrome: 2 people, 9.52%
Hypogammaglobulinaemia (an abnormally low concentration of gamma globulin in the blood and increased risk of infection): 1 person, 4.76%
Hereditary Neuropathic Amyloidosis (hereditary- diseases resulting from abnormal deposition of certain proteins (amyloid) in various bodily areas by problems with signals from the nerves): 1 person, 4.76%
Fainting (loss of consciousness and postural tone): 1 person, 4.76%
Autonomic Neuropathy (malfunction of the autonomic nervous system (ans)): 1 person, 4.76%
Amyloidosis Senile (common form of amyloidosis in very old people, usually mild and limited to the heart): 1 person, 4.76%

* Approximation only. Some reports may have incomplete information.

Do you take Estrace and have Infusion site extravasation?

- Check whether Infusion site extravasation is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Estrace:

Estrace (16,703 reports)

Browse all side effects of Estrace:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Infusion site extravasation:

Infusion site extravasation (649 drugs)

Browse all the conditions that are associated with Infusion site extravasation:

Infusion site extravasation (588 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on estradiol (the active ingredients of Estrace) and Estrace (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.